key: cord-0788535-3vqsgfqv authors: Tan, Q.; Jin, Y. title: Ostavimir is ineffective against COVID-19: in silico assessment, in vitro and retrospective study date: 2020-05-20 journal: nan DOI: 10.1101/2020.05.15.20102392 sha: d67bde9562f1867b703627fcea29870a22305b59 doc_id: 788535 cord_uid: 3vqsgfqv As a neuraminidase inhibitor, oseltamivir has effectively combated the pandemic influenza A and B, so it is a first-line commonly used antiviral drug, especially in primary hospitals. At the same time, oseltamivir, as an over-the-counter drug, is also a popular antiviral drug. As healthcare workers fighting against coronavirus disease 2019 (COVID-19), we have found that many patients experiencing discomfort or considered to be infected with a virus take oseltamivir. From severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 to middle east respiratory syndrome coronavirus (MERS-CoV) in 2012, and now the current COVID-19 epidemic, there is not plenty of evidence showing that oseltamivir is effective against coronavirus. Still, there is also no sufficient evidence to refute its ineffectiveness. We cannot predict whether there will be a pandemic of respiratory coronavirus in the future, so we hope to initiate such research and preliminarily explore whether oseltamivir is effective for COVID-19, which can better guide healthcare workers in the selection of appropriate antiviral drugs in the face of coronavirus epidemics. If oseltamivir is effective, then a wide promotion of its application often can achieve a double effect with half the effort. If it is not effective, then considering the side effects of oseltamivir, it is not necessary to use unreasonable drugs that will not slow the progression of the disease but can cause adverse reactions. We found that oseltamivir is not suitable for fighting against COVID-19 through the method of computer aided drug design and in vitro study and retrospective case study. Meanwhile it was high-occurrence seasons for the influenza, COVID-19 should be highly suspected in patients who did not benefit from oseltamivir. We hope that the result of our study could be shared with the frontline physicians in fighting against COVID-19. Admission (FDA) in 1999 1 . Since then, it has played an essential role in treating against influenza A and influenza B and is becoming more widespread. The atypical pneumonia caused by severe acute respiratory syndrome coronavirus (SARS-CoV) that broke out in Guangzhou, China, in 2003, linked oseltamivir to coronavirus. Zhang et al. found that the active site of the Spike (S) 1 Protein of SARS is similar to that of neuraminidase, suggesting that neuraminidase inhibitors may be useful to treat SARS-CoV 2 . However, despite this similarity, no clinical data suggest that oseltamivir is effective in treating SARS-CoV. With the epidemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, oseltamivir has once again become a hot topic. A study from Thailand reported that a 71-year-old patient with severe COVID-19 on January 29, 2020 underwent a 48-hour treatment with lopinavir/ritonavir combined with oseltamivir, which improved the patient's condition, and the throat swab test became negative 3 . Although a single case report does not prove the effectiveness of oseltamivir for COVID-19, it once again linked oseltamivir to the treatment of a coronavirus-induced disease. As frontline healthcare workers fighting against COVID-19, we were interested in the treatment regimen of this case and found most patients with COVID-19 who were symptomatic have used oseltamivir. We believed that it is of practical significance to further study the effect of oseltamivir on COVID-19. Because of its significant effectiveness on influenza and being sold over the counter, oseltamivir is not only stocked in common households but also a common antiviral drug in primary hospitals. Therefore, if oseltamivir is effective for COVID-19, the treatment could be family-oriented. If, instead, the treatment effectiveness is not significant, the use of oseltamivir should be stopped, which will avoid delaying other . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 20, 2020. The structures of the S protein (PDB ID: 6VSB) and 3CL pro (PDB ID: 6LU7) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 20, 2020. . Inhibiting NRBD activity can affect coronavirus RNA transcription and replication, and virion assembly 16 . Thus, it is one of the targets for inhibiting coronaviruses. Therefore, NRBD is the main activity center of NC, and this model can be used for the active site of NC from SARS-CoV-2 for further research. were in the most favored region. The results are shown in Fig 1D, suggesting all three models passed the evaluation. Among them, the ERRAT score was based on whether the error value of the alignment of the non-bonding interaction among the atoms in the . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2020. . https://doi.org/10.1101/2020.05.15.20102392 doi: medRxiv preprint structure and the high-resolution crystal structure was within a reasonable confidence interval. If the percentage of the reasonable confidence interval is higher, the quality is higher. Almost all residues of NRBD, Pol/RdRp, and PLpro were within reasonable confidence intervals, and the final scores were 96.4602, 95.9157, and 92.7586, respectively (Fig1A-C). Verify3D was used to analyze the compatibility of the 3D structure and the primary sequence in the model. A 3D-1D score To explore whether oseltamivir is effective for SARS-CoV-2, we first analyzed whether there was structural similarity between the structure of viral protein and influenza A neuraminidase (PDB ID: 3Ti6), especially whether there was a similarity in the active center. TM-align program . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2020. . (https://zhanglab.ccmb.med.umich.edu/TM-align/) was used for structural alignment 17 . The alignment of the structure of influenza B neuraminidase (PDB ID: 4CPY) with 3Ti6 was selected as a positive control. TM-score was used to analyze the structural similarity; 0.0 < TM-score < 0.30 was defined as "random structural similarity", and 0.5 < TM-score < 1.00 was defined as "in about the same fold". The active site of influenza A and B neuraminidase were determined based on the location of ligand in crystal structure ( Fig. 2A) 18, 19 . By comparing 4CPY with 3Ti6, the TM-score of the two was found to be 0.94460, which proved that the two were structurally homologous. Subsequently, we aligned the structures of S protein, NRBD, 3CL pro, PLpro, and Pol/RdRp with 3Ti6; the TM-scores were 0.30077, 0.19254, 0.28766, 0.30666, and 0.34047, respectively (Fig. 2G) . The results suggested that there was only a structural similarity between the protein structure of the above SARS-CoV-2 and 3Ti6. The active center of the S protein was mainly the RBD domain ( Fig. 2B green region) and S2 subunit HR1 domain (Fig. 2B blue region) , which were also two important targets for studying the inhibition of S protein 20, 21 . We found that the similar structure of 3Ti6 and S protein is located in the N-terminal domain (NTD) region of S protein. As the active center of NC, we found that NRBD did not match the active center of 3Ti6 (Fig2C). The active center of 3CLpro was determined based on that it is homologous to the 3CLpro from SARS-CoV. Previous studies have confirmed the active center of 3CLpro of SARS-CoV. Thus, this region was used as the active center of 3CLpro of SARS-CoV-2 12 . By alignment, we found that the active centers of the two proteins were similar (Fig. 2D) . Subsequently, we also determined the active center of the PLpro and Pol/RdRp based on the homology of the proteins of SARS-CoV-2 and those of SARS-CoV. And we found that the active center of PLpro did not match the active center from 3Ti6 through the alignment of structure (Fig. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2020. . https://doi.org/10.1101/2020.05.15.20102392 doi: medRxiv preprint 2E) 22 . In studies focused on the Pol/RdRp of SARS-CoV, it has found that Thr680, Asn691, and Asp623 can bind nucleotides and promote viral gene transcription, and Val557 also plays an important role in the replication of the virus 19 . Thus, the region where the above residues are located was determined as the active center of SARS-CoV-2 (Fig. 2F) . It was found that the similar structure between Pol/RdRp and neuraminidase was not located in the active center. The above results suggested that there was a theoretical possibility of effective binding of oseltamivir with the active center of 3CLpro because it was found to be similar to the active center from the neuraminidase. To pursue our hypothesis, we used molecular docking to analyze whether oseltamivir carboxylic acid could stably bind to the active center of the viral protein structure. We used ChemBioDraw Ultra 17.0 software to draw the structure of oseltamivir carboxylic acid and N3 inhibitor, then converted them into three-dimensional (3D) structure using ChemBio3D Ultra 17.0 software. Then the structure of agents was preprocessing by MMFF94 force field. AutoDock Tools 1.5.6 software was used to remove water molecules and ligands in the protein, and then add hydrogen atoms, combine non-polar hydrogen atoms, add charges, and converted protein and drugs into the format of PDBQT. The GridBox module was used to generate a 3D ensemble around the active site, and the grid points in the ensemble were calculated for energy score evaluation. AutoDock Vina was used for molecular docking 23 . Exhaustiveness was set at 20 and other parameters were used default value. Finally, we selected the conformation with the highest docking score to analyze the result using Free Maestro 11.9. The docking conformations were described in Fig3A-E. The results showed that the docking energies of oseltamivir carboxylic acid . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2020. . https://doi.org/10.1101/2020.05.15.20102392 doi: medRxiv preprint with NRBD, 3CLpro, PLpro, and Pol/RdRp were −4.7 kcal/mol, −7.0 kcal/mol, −5.8 kcal/mol, and −5.4 kcal/mol, respectively (Fig3F). The lower the binding energy, the more suitable the binding of the inhibitor molecule to the receptor. In terms of binding energy, oseltamivir carboxylic acid was more favorable to bind to the active site of 3CLpro effectively. However, we concluded that the ability of oseltamivir to inhibit 3CLpro is not strong compared with N3 inhibitor, which exhibited strong inhibition for 3CLpro of SARS-CoV-2 in vitro and its docking energy was −9.5 kcal/mol 24 , which was lower than that of oseltamivir carboxylic acid. To further verify our hypothesis, we evaluated the antiviral efficiency of oseltamivir against SARS-CoV-2 in vitro as described in the previous work 25 Therefore, we concluded that oseltamivir is ineffective against SARS-CoV-2. To further verify the efficacy of oseltamivir on SARS-CoV-2, we retrospectively . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2020. . https://doi.org/10.1101/2020.05.15.20102392 doi: medRxiv preprint patients were diagnosed with COVID-19 and negative for influenza A and B nucleic acid tests; 2. there were no other underlying diseases, such as hypertension, diabetes, cardiovascular and cerebrovascular diseases, malignant diseases, no respiratory tract diseases, such as COPD, asthma, and pulmonary heart disease, and no hypoproteinemia and hypokalemia. The patients' age and sex were obtained from electronic medical records. We defined the period from the start of antiviral therapy to clinical evaluation as a patients' treatment period. We defined the patients with relieved symptoms and stable or absorbed lesions in CT during the treatment period as the remission group, and the patients without symptom improvement or no significant changes or progression of the lesions in CT as the progressive group. Whether the history of oseltamivir use influenced the progression of the disease was statistically evaluated. Chi-square test was used to determine differences between group remission and progressive. P-values < 0.05, < 0.01, and < 0.001 were considered significant. Finally, 79 patients were included for analysis. Among them, there were 31 patients in remission, aged 50.77 ± 14.919. There were 48 non-remission patients, and their age was 50.52 ± 15.062. There was no significant difference in age between the two groups. In the remission group, there were 12 males (with a proportion of 38.7%), and in the non-remission group there were 25 males (52.1%); there was no statistical difference in sex between the two groups. We analyzed the use of oseltamivir in the two groups. In the remission group, a total of seven patients used oseltamivir with a proportion of 22.6%. In the non-remission group, a total of 35 patients used oseltamivir, with a proportion of 72.9%. The chi-square value was 19.166, and there was a significant statistical difference between the two groups. The number of patients receiving oseltamivir in the non-remission group was significantly higher than the number in the remission group (P = 0.000) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 20, 2020. . (Fig.4C-D) . In combination with clinical practice, we believe that oseltamivir had no inhibitory effect on COVID-19 and could not effectively slow the progression of the disease with early use. In this article, we constructed protein models of NRBD, PLpro, and Pol/RdRp of SARS-CoV-2. We used structural alignment to find that the active center of 3CLpro was similar to that of influenza A neuraminidase. Subsequently, we used a molecular docking method to explore whether oseltamivir could effectively bind to the NRBD, 3CLPro, PLpro, and Pol/RdRp of SARS-CoV-2. It was found that oseltamivir carboxylic acid was more favorable to bind to the active site of 3CLpro effectively, but its inhibitory effects was not strong. Finally, we used in vitro study and retrospective case analysis to verify our speculations. We found that oseltamivir is ineffective against SARS-CoV-2 in vitro study and the clinical use of oseltamivir did not improve the patients' symptoms and signs and did not slow the disease progression. Therefore, we consider that oseltamivir isn't suitable for the treatment of COVID-19. During the outbreak of novel coronavirus, when oseltamivir is not effective for the patients after they take it, health workers should be highly vigilant about the possibility of COVID-19. At the same time, it should be noted that we are still in the influenza season, and we have also found five cases of influenza A in combined with COVID-19. Therefore, oseltamivir should be combined in the treatment regimen in a timely manner when influenza occurs. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 20, 2020. . https://doi.org/10.1101/2020.05.15.20102392 doi: medRxiv preprint oseltamivir in the remission group and those in the non-remission group. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 20, 2020. . https://doi.org/10.1101/2020.05.15.20102392 doi: medRxiv preprint in experimental human influenza: randomized controlled trials for prevention and treatment The 3D structure analysis of SARS-CoV S1 protein reveals a link to influenza virus neuraminidase and implications for drug and antibody discovery Combining the medications improved conditions in patients with severe 2019-nCoV infections, say doctors in Thailand Australian medicines handbook: Sydney Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission Coronaviruses: an overview of their replication and pathogenesis Origin and evolution of pathogenic coronaviruses Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds Identification of effective siRNA blocking the expression of SARS viral envelope E and RDRP genes Antiviral drug discovery against SARS-CoV Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein TM-align: a protein structure alignment algorithm based on the TM-score Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses A pan-coronavirus fusion inhibitor targeting the HR1